_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc-preview-1.jpg "PROpel: olaparib plus abiraterone as 1L treatment for metastatic CRPC from olaparib prostate cancer Video Screenshot Preview 1")
Gallery_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc-preview-3.jpg "PROpel: olaparib plus abiraterone as 1L treatment for metastatic CRPC from olaparib prostate cancer Video Screenshot Preview 3")
Gallery_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc-preview-hqdefault.jpg "PROpel: olaparib plus abiraterone as 1L treatment for metastatic CRPC from olaparib prostate cancer Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 3 minutes 7 seconds
👁 View: 372 times
Play Audio:👁 View: 372 times
Description:
VJOncology
VJOncology
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.webp "Vall d'Hebron Institute of Oncology - VHIO")
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.webp "VJOncology")
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.webp "VJOncology")
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.webp "Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agents in advanced castration resistant prostate cancer.nnShe reports that in cohort A (patients with BRCA1, BRCA2 or ATM genes) progression free survival was over double in favour of the olaparib and in the overall population of cohort A and cohort B (alterations in other genes involved in DNA repair) there were similar trends.nnProf Hussain be")
⏲ 3 min 98 sec ✓ 30-Sep-2019
_rucaparib-and-olaparib-two-new-treatments-approved-for-advanced-prostate-cancer-124-pcri.webp "Prostate Cancer Research Institute")
⏲ 5 minutes 15 seconds 👁 1.8K
_parp-inhibitors-for-prostate-cancer.webp "Cleveland Clinic")
_targeted-therapy-recent-advances-in-prostate-cancer-from-esmo-2019.webp "Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA), Prof Noel Clarke (The Christie NHS Foundation Trust, Manchester, UK), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Matthew Smith (Massachusetts General Hospital Cancer Center, Boston, USA) discuss the key developments presented at ESMO 2019 on targeted therapies in prostate cancer. nnThe panel discuss the latest data from the STAMPEDE trial and the use of docetaxel in high-volume disease versus lo")
Related Video Searches
Back to Search
Search Videos
Recent Searches
×
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.jpg)
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.jpg)
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg)
_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc.jpg)
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.jpg)
_rucaparib-and-olaparib-two-new-treatments-approved-for-advanced-prostate-cancer-124-pcri.jpg)
_parp-inhibitors-for-prostate-cancer.jpg)
_targeted-therapy-recent-advances-in-prostate-cancer-from-esmo-2019.jpg)
❮❯
1 / 12
2 / 12
3 / 12
4 / 12
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
5 / 12
6 / 12
7 / 12
8 / 12
9 / 12
10 / 12
11 / 12
12 / 12
View Full Screen: propel olaparib plus abiraterone as 1l treatment for metastatic crpc preview 1.jpg
![[+]](/images/menu.gif){kind=small}